论文部分内容阅读
目的观察更昔洛韦治疗婴儿巨细胞病毒（ＣＭＶ）肝炎的疗效。方法将６０例ＣＭＶ肝炎婴儿随机分成两组。治疗组（ｎ＝３１）在常规护肝的基础上加用更昔洛韦５ｍｇ／ｋｇ静脉点滴，每日２次，连续１４ ｄ。对照组（ｎ＝２９）予常规护肝治疗。结果治疗组的治愈率和好转率为４８．４％和３８．７％，对照组分别为２４．１％和３４．５％（ Ｐ＜０．０５）。治疗组较对照组黄疸消退平均提前１０．２ ｄ，ＡＬＴ恢复正常平均提前７．１ｄ（ Ｐ＜０．０５）。治疗组治疗后ＣＭＶ—ＤＮＡ阴转率为６０．０％，显著高于对照组的１４．３％。未见粒细胞或血小板减少。结论更昔洛韦是治疗婴儿ＣＭＶ肝炎的有效药物。
Objective To observe the curative effect of ganciclovir on infant cytomegalovirus (CMV) hepatitis. Methods Sixty infants with CMV hepatitis were randomly divided into two groups. In the treatment group (n = 31), ganciclovir 5 mg / kg was intravenously administered twice daily for 14 days on the basis of conventional liver protection. The control group (n = 29) received routine liver protection. Results The cure rate and improvement rate were 48.4% and 38.7% in the treatment group and 24.1% and 34.5% in the control group (P <0.05). The treatment group than the control group jaundice an average of 10.2 days earlier, ALT returned to normal average 7.1d (P <0.05). CMV-DNA negative conversion rate after treatment in the treatment group was 60.0%, which was significantly higher than that in the control group (14.3%). No granulocytes or thrombocytopenia were observed. Conclusion Ganciclovir is an effective drug for the treatment of CMV hepatitis in infants.